Triple-Punch cell therapy aims to outsmart tough childhood leukemia
NCT ID NCT05010564
Summary
This early-phase study is testing a new, experimental cell therapy called TRICAR-ALL for children and young adults (ages 1-25) whose B-cell acute lymphoblastic leukemia (ALL) has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to recognize and attack three specific markers (CD19, CD20, CD22) on leukemia cells, and then infuse them back into the patient. The main goal of this first-in-human study is to find a safe dose and see how long these modified cells last in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.